Jun Ding
12 Papers
1 Citations
Jun Ding is an academic researcher. The author has contributed to research in topics: Oncolytic virus & Biology. The author has an hindex of 2, co-authored 8 publications.
Chat about Author
Papers
mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge.
Fujun Hou,Xiaohu Liu,Yanal M Murad,Jiang Xu,Zhibin Yu,Xianwu Hua,Yingying Song,Jun Ding,Ronghua Zhao,William Jia,Xiaoming Yang +10 more
TL;DR: The results suggest that the VGPox series vaccines enhance immunogenicity and can be a viable alternative to current whole-virus vaccines to defend against mpox.
41
Pre-Existing HSV-1 Immunity Enhances Anticancer Efficacy of a Novel Immune-Stimulating Oncolytic Virus
TL;DR: The anticancer efficacy of VG161 can be enhanced by pre-immunization with HSV-1 and multicycle administration when the virus is given intratumorally, indicating that pre-existing antiviral immunity might enhance OV-induced antitumor immunity.
Novel mRNA vaccines encoding Monkeypox virus M1R and A35R protect mice from a lethal virus challenge
Fujun Hou,Yuntao Zhang,Xiaohu Liu,Yanal Murad,Jiang Xu,Zhibin Yu,Xianwu Hua,Yingying Song,Jun Ding,Hongwei Huang,Ronghua Zhao,William Jia,Xiaoming Yang +12 more
TL;DR: In this article , the authors developed three mRNA vaccines encoding Monkeypox proteins M1R and A35R, including a 35R-M1R fusions (VGPox1 and VGPox 2) and a combination of encapsulated full-length mRNAs for A 35R and M1r (VPGox 3).
Combination of novel oncolytic herpesvirus with paclitaxel as an efficient strategy for breast cancer therapy
Xinyue Deng,Yinan Shen,Ming Yi,Chaomei Zhang,Guansheng Zhong,Dixuan Xue,Qi Leng,Jun Ding,Ronghua Zhao,Weiguo Jia,Chenfang Dong,Zhijun Dai +11 more
TL;DR: In this paper , a replicable recombinant oncolytic herpes simplex virus type 1 called VG161 has been developed and has demonstrated antitumor effects in several cancers.
10
Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine
Changrui Lu,Yuntao Zhang,Xiaohu Liu,Fujun Hou,Rujie Cai,Zhibin Yu,Meilin Liu,Guohuan Yang,Jun Ding,Jiang Xu,Xianwu Hua,Xinping Pan,Lianxiao Liu,Kang Lin,Zejun Wang,Xinguo Li,Jia Lu,Qiu Zhang,Yuwei Li,Chunxia Hu,Huifeng Fan,Xiaoke K. Liu,Hui Wang,Rui Jia,F. Xu,Xue-Wei Wang,Hongwei Huang,Ronghua Zhao,Jing Li,Hang Cheng,William Jia,Xiaoming Yang +31 more
TL;DR: In this paper , two mRNA vaccines ZSVG-02 (Delta) and ZSVM-02-O (Omicron BA.1), and associating heterologous prime-boost strategy following the prime of a most widely administrated inactivated whole-virus vaccine (BBIBP-CorV).
5